Table 3.
Univariate and multivariate Cox regression analysis adjusted heart failure medication
| Variances | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| OR | 95 % CI | Р value | OR | 95 % CI | Р value | |
| Creatinine per 30 μmol/L | 1.06 | 1.01–1.11 | 0.001 | 1.02 | 0.87–1.06 | 0.44 |
| Fasting glucose per 3 mmol/L | 1.04 | 0.96–1.09 | 0.22 | Not included | ||
| HbA1c per 1 % | 1.05 | 1.00–1.07 | 0.12 | Not included | ||
| Total cholesterol per 1 mmol/L | 1.08 | 1.00–1.09 | 0.12 | Not included | ||
| Uric acid per 10 mmol/L | 1.08 | 1.03–1.09 | 0.001 | 1.03 | 0.92–1.08 | 0.52 |
| NT-pro-BNP per 400 pg/mL | 1.97 | 1.25–3.06 | 0.001 | 1.37 | 1.08–2.10 | 0.001 |
| Galectin-3 per 2.5 ng/mL | 2.16 | 1.78–3.77 | 0.001 | 1.46 | 1.22–1.89 | 0.003 |
| hs-CRP per 1 mg/L | 1.42 | 1.22–1.87 | 0.001 | 1.12 | 1.03–1.25 | 0.001 |
| Osteoprotegerin per 325 pg/mL | 1.34 | 1.18–1.62 | 0.006 | 1.19 | 1.12–1.33 | 0.001 |
| Osteopontin per 65 ng/mL | 1.16 | 1.03–1.36 | 0.002 | 0.95 | 0.87–1.11 | 0.86 |
| Osteonectin per 50 ng/mL | 1.19 | 1.07–1.28 | 0.001 | 1.06 | 0.91–1.19 | 0.72 |
| sRANKL per 100 pg/mL | 1.08 | 1.02–1.15 | 0.001 | 1.02 | 0.86–1.07 | 0.66 |
| sRANKL/osteoprotegerin per 0.15 units | 1.56 | 1.23–1.72 | 0.002 | 1.17 | 1.04–1.25 | 0.003 |
| Adiponectin per 3.5 μg/mL | 1.05 | 1.01–1.09 | 0.006 | 1.03 | 0.89–1.07 | 0.54 |
| CD14+CD309+ MPCs per 10 × 10−4% | 1.12 | 1.05–1.27 | 0.001 | 1.05 | 1.00–1.11 | 0.01 |
| CD14+CD309+Tie2+ MPCs per −0,2 × 10−4% | 1.15 | 1.03–1.29 | 0.006 | 1.06 | 1.01–1.09 | 0.001 |
| CD31+/annexin V+ EMPs per 0.2 cells/mL | 1.18 | 1.10–1.27 | 0.001 | 1.07 | 1.02–1.13 | 0.001 |
| CD31+/annexin V+ EMPs to CD14+CD309+ MPCs per 2.5 × 10 units | 2.14 | 1.18–3.55 | 0.001 | 1.19 | 1.12–1.27 | 0.001 |
Notes: CI confidence interval, OR odds ration, HbA1c glycated hemoglobin, BNP brain natriuretic peptide, sRANKL serum receptor activator of nuclear factor-kappa B ligand, EMPs endothelial-derived apoptotic microparticles, MPCs mononuclear progenitor cells